MetaboXcan: A multiomic framework linking genetically predicted metabolites, gene expression, and complex traits
Nyasimi, F.; Sumner, S.; Liang, Y.; Yin, X.; Park, Y.; Brown, A.; Lawal, S. A.; Vinuela, A.; Fernandez Silva, L.; Liu, C.; Slack, S. D.; Esquinca, E.; Johnson, R. K.; Kechris, K.; Laasko, M.; Boehnke, M.; Fauman, E.; Palmer, A. A.; Sanchez-Roige, S.; Manichaikul, A.; Palmer, N. D.; Im, H. K.
Show abstract
Genetically regulated molecular phenotypes, such as gene expression and metabolites, are widely thought to mediate the effect of disease-relevant genetic loci identified by genome-wide association studies (GWAS); however, molecular mechanisms connecting genetic variation to disease remain poorly understood. While transcriptome-wide association studies (TWAS) have identified disease-associated genes, strategies that integrate the metabolome remain underexplored. Here, we introduce MetaboXcan, a framework for predicting plasma metabolite levels from genetic data and associating them with complex traits using GWAS summary statistics. We trained lasso regression models on plasma metabolite and genotype data from the Metabolic Syndrome in Men Study (METSIM); these models outperform existing genetic metabolite predictors and generalize well across independent cohorts. MetaboXcan leverages these models to perform four complementary association analyses: (i) gene-to-trait (TWAS), (ii) gene-to-metabolite (M-TWAS), (iii) metabolite-to-trait (MWAS), and (iv) gene-expression-based metabolite-to-trait associations (g-MWAS). The framework further organizes results into metabolic pathways and gene-metabolite interaction networks to facilitate biological interpretation. Applied to chronic kidney disease (CKD), MetaboXcan identified known disease risk genes (PDILT/UMOD, SPATA5L1/GATM), as well as multiple CKD-relevant metabolites (e.g., glycine, homoarginine). Our integrated multiomic analysis enables biological interpretation by revealing glycine availability-centered biochemical axes spanning oxidative stress, cellular energetics, and vascular signaling, while nominating candidate mechanisms for downstream investigation. These results validate known disease-related biology with genetic evidence and generate new hypotheses for further investigation. MetaboXcan is publicly available and broadly applicable to any GWAS phenotype.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Genome-wide characterization of 54 urinary metabolites reveals molecular impact of kidney function 96%
- Metabolome-wide Mendelian randomization characterizes heterogeneous and shared causal effects of metabolites on human health 96%
- Genetic analysis of blood molecular phenotypes reveals regulatory networks affecting complex traits: a DIRECT study 96%
Similar papers in this journal
- Polygenic scores capture genetic modification of the adiposity-cardiometabolic risk factor relationship 95%
- Multi-trait genome-wide association study in 34,394 Chinese women reveals the genetic architecture of plasma metabolites during pregnancy 95%
- Proteome-wide Mendelian randomization in global biobank meta-analysis reveals multi-ancestry drug targets for common diseases 94%
Similar papers in this journal
Similar papers in this journal
- Pathway-specific polygenic scores substantially increase the discovery of gene-adiposity interactions impacting liver biomarkers 96%
- Genome-wide association study reveals shared and distinct genetic architecture underlying fatty acid and bioactive oxylipin metabolites in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) 96%
- An LDLR missense variant poses high risk of familial hypercholesterolemia in 30% of Greenlanders and offers potential for early cardiovascular disease intervention 92%
Similar papers in this journal
- Metabolite Signature of Life’s Essential 8 and Risk of Coronary Heart Disease among Low-Income Black and White Americans 94%
- Metabolic dysregulation of the lysophospholipid/autotaxin axis in the chromosome 9p21 gene SNP rs10757274 94%
- Augmenting clinical risk prediction of cardiovascular disease through protein and epigenetic biomarkers 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.